• Author Reply

    Feb 1, 2025, 00:00

  • Modeling the Potential Health, Health Economic, and Health Inequality Impact of a Large-Scale Rollout of the Drink Less App in England

    Feb 1, 2025, 00:00

  • Financial Impacts of Paying for Gene Therapy for Sickle Cell Disease Under Alternative Pricing and Financing Mechanisms

    Feb 1, 2025, 00:00

  • Slipping Away: Slippage in Hazard Ratios Over Datacuts and Its Impact on Immuno-oncology Combination Economic Evaluations

    Feb 1, 2025, 00:00

  • A Standardized Measurement and Valuation Scale of Genomic Utility for Policy Decisions: The GUV Scale

    Feb 1, 2025, 00:00

  • A Systematic Review and Quality Assessment of Cardiovascular Disease–Specific Health-Related Quality-of-Life Instruments: Part II Psychometric Properties

    Feb 1, 2025, 00:00

  • Measurement Equivalence of Standard and Zoom-Enabled Electronic Clinical Outcome Assessments: Implications for Patient Accessibility in Clinical Trials

    Feb 1, 2025, 00:00

  • Healthcare Costs in the United States by Demographic Characteristics and Comorbidity Status

    Feb 1, 2025, 00:00

  • Value Framework Based on Multiple-Criteria Decision Analysis for Assessment of New Health Technologies Under Universal Healthcare Coverage System in Taiwan

    Feb 1, 2025, 00:00

  • Reporting Uncertainty Around Health-State Values: A Standard Method and Worked Example

    Feb 1, 2025, 00:00

  • The Cost-Effectiveness of Frontline Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia: In Pursuit of Treatment-Free Remission and Dose Reduction

    Feb 1, 2025, 00:00

  • Editorial Board

    Jan 31, 2025, 10:40

  • Editorial Board

    Jan 8, 2025, 14:39

  • Value Attribution for Combination Treatments: Two Potential Solutions for an Insoluble Problem

    Jan 1, 2025, 00:00

  • Primer on Health Equity Research in Health Economics and Outcomes Research: An ISPOR Special Interest Group Report

    Jan 1, 2025, 00:00

  • Most Common Symptomatic Adverse Reactions of Cancer Treatments From US Drug Labels (2015-2021) to Inform Selection of Patient-Reported Outcomes

    Jan 1, 2025, 00:00

  • Good Practices for Health Technology Assessment Guideline Development: A Report of the Health Technology Assessment International, HTAsiaLink, and ISPOR Special Task Force

    Jan 1, 2025, 00:00

  • Dysmenorrhea-Related Impact on Functioning Scale: Development and Measurement Properties for Cisgender Women and Transgender Men

    Jan 1, 2025, 00:00

  • Exploring Heterogeneity in the Cost-Effectiveness of High-Flow Nasal Cannula Therapy in Acutely Ill Children—Insights From the Step-Up First-line Support for Assistance in Breathing in Children Trial Using a Machine Learning Method

    Jan 1, 2025, 00:00

  • An Attribution of Value Framework for Combination Treatments

    Jan 1, 2025, 00:00

  • Will the Institute for Clinical and Economic Review’s Shared Savings Approach Decrease Value-Based Prices Most for the Most Severe Diseases?

    Jan 1, 2025, 00:00

  • Deriving a Preference-Weighted Measure for People With Hypoglycemia From the Hypo-RESOLVE QoL

    Jan 1, 2025, 00:00

  • Unpaid Caring and Health-Related Quality of Life: Longitudinal Analysis of Understanding Society (the UK Household Longitudinal Survey)

    Jan 1, 2025, 00:00

  • Challenges in Value Assessment for One-Time Gene Therapies for Inherited Retinal Diseases: Are We Turning a Blind Eye?

    Jan 1, 2025, 00:00

  • Cancer Drug Wastage and Mitigation Methods: A Systematic Review

    Jan 1, 2025, 00:00

  • Analytical Methods for Comparing Uncontrolled Trials With External Controls From Real-World Data: A Systematic Literature Review and Comparison With European Regulatory and Health Technology Assessment Practice

    Jan 1, 2025, 00:00

  • Proposal for a General Outcome-Based Value Attribution Framework for Combination Therapies

    Jan 1, 2025, 00:00

  • Economic Evaluation of Fasting Mimicking Diet Versus Standard Care in Diabetic Patients on Dual or Triple Medications at Baseline in the United States: A Cost-Utility Analysis

    Jan 1, 2025, 00:00

  • Development of a Health-State Classification System for the Pediatric Quality-of-Life Inventory Version 4.0 Generic Core Scales for Preference-Based Valuation in Australia

    Jan 1, 2025, 00:00

  • A Review and Comparative Case Study Analysis of Real-World Evidence in European Regulatory and Health Technology Assessment Decision Making for Oncology Medicines

    Jan 1, 2025, 00:00

  • Virtual/Mobile Overdose Response in Canada: A Social Return on Investment Analysis

    Jan 1, 2025, 00:00

  • Table of Contents

    Jan 1, 2025, 00:00

  • Editorial Board

    Dec 3, 2024, 18:32

  • CO125 The Impact of Insulin Dosage on Cancer Risk in Type 1 Diabetes: A Population-Based Study

    Dec 1, 2024, 00:00

  • EE458 Evaluating Utilization Patterns, Financial Impact, and Access Delay Caused by Reimbursement Criteria on Public Drug Plans for Primary Care Topical Treatments in Canada: Case Study With HP/TAZ Combination for Plaque Psoriasis

    Dec 1, 2024, 00:00

  • HSD94 Economic Impacts of Artificial Intelligence (AI)-Based Risk Analytics for Early Detection of Clinical Deterioration in a Pragmatic Randomized Controlled Trial: Need for Innovative Approaches to Understand Costs for AI Systems

    Dec 1, 2024, 00:00

  • CO24 Modeling Cardiovascular Event Reduction and Cost Savings With a CV Polypill (ASA + Atorvastatin + Ramipril) Versus Individual Components Post-Myocardial Infarction in Spain

    Dec 1, 2024, 00:00

  • HPR253 Drug Development and Launch Timeline Analysis Across 6 High-Income Countries: From Pivotal Trial to HTA

    Dec 1, 2024, 00:00

  • EE503 Key Features of Economic Models Used in Submissions to NICE in Dermatology Indications

    Dec 1, 2024, 00:00

  • HPR120 Is the Speed of Biosimilar Penetration Related to Demand-Side Polices?

    Dec 1, 2024, 00:00

  • P5 Air Pollution Control and Health Economic Burdens: Evidence From a Megacity in China From 2014 to 2022

    Dec 1, 2024, 00:00

  • EE654 Economic Modelling Approaches for Evaluating Interventions That Reduce Surgery Waiting Times

    Dec 1, 2024, 00:00

  • EE647 Budget Impact Analysis of Fixed-Duration Ibrutinib+Venetoclax As Frontline Treatment of Chronic Lymphocytic Leukemia in the Brazilian Private Healthcare System

    Dec 1, 2024, 00:00

  • HTA84 Validation of the AI-Based Early Reimbursement Planning Search Engine in Main European Countries and the USA

    Dec 1, 2024, 00:00

  • EE401 Budgetary Impact of Pre-Therapeutic DPD Deficiency Screening in Fluoropyrimidine-Treated Cancer Patients in Algeria

    Dec 1, 2024, 00:00

  • CO43 Comparison of Novel Multilevel-Network Meta-Regression With Other Conventional Indirect Treatment Comparisons

    Dec 1, 2024, 00:00

  • EE580 Cost-Utility of Acromegaly Second Line Pharmacological Treatments in Adult Patients in France

    Dec 1, 2024, 00:00

  • HTA197 Recent Trends From UKs Cancer Drugs Fund, Key Drivers of Acceptance

    Dec 1, 2024, 00:00

  • EE702 A QALY is a QALY is a QALY: Nope

    Dec 1, 2024, 00:00

  • HPR135 Current Barriers and Strategies for Optimizing Access to Onco-Hematological Drug Combinations in Spain: Multidisciplinary Delphi Consensus

    Dec 1, 2024, 00:00

  • EPH96 The Impact of Influenza in Older Age Groups in Portugal, 2015-2018

    Dec 1, 2024, 00:00

  • CO28 Analysis of Prophylactic Treatment of Patients With Hereditary Angioedema in the Slovak Republic in 2022: Results of the Descriptive Cross-Sectional Database Study

    Dec 1, 2024, 00:00

  • EPH163 Economic Burden Associated With Post-Partum Hemorrhage: A Targeted Literature Review

    Dec 1, 2024, 00:00

  • EPH190 Real-World Treatment of Newly Diagnosed Patients With Acute Myeloid Leukemia and Aged Between 60 and 75 Years: Analysis of Key Drivers for Chemotherapy Selection in France and Germany

    Dec 1, 2024, 00:00

  • HPR248 Willingness to Pay for Ultra-Rare Diseases in US, Germany, France, UK, and Japan: A Comparative Study

    Dec 1, 2024, 00:00

  • EE418 Cost-Utility Analysis of Flash Glucose Monitoring Systems in People With Type 2 Diabetes Mellitus and Poor Glycemic Control on Basal Insulin From the Spanish Health System Perspective

    Dec 1, 2024, 00:00

  • HPR97 More Public Funding? A Choice Experiment on the Healthcare Funding System for Older Populations

    Dec 1, 2024, 00:00

  • EE794 Assessing the Impact of Introducing Mavacamten for the Treatment of Obstructive HCM on the Modelled System and Societal Level Burden in China

    Dec 1, 2024, 00:00

  • EE739 Estimated Incremental Direct All-Cause Healthcare Costs Associated With Multimorbidity Amongst Patients With Sickle Cell Disease (SCD) in England

    Dec 1, 2024, 00:00

  • EPH80 Impact of the COVID-19 Pandemic on Arterial Hypertension Monitoring and Control in Portugal

    Dec 1, 2024, 00:00

  • EE709 Cost-Effectiveness Analysis of Paxlovid® (Nirmatrelvir+Ritonavir) in Adults at High-Risk of Progression to Severe COVID-19 Disease in Portugal

    Dec 1, 2024, 00:00

  • HTA190 Using Real-World Evidence in Health Technology Assessment Submissions: A NICE Case Study

    Dec 1, 2024, 00:00

  • EPH243 First Real-World Evidence Onbudesonide/Glycopyrronium/Formoterol Fumarate(BGF) Use for COPD Patients in France (ENARXI Study)

    Dec 1, 2024, 00:00

  • CO64 Systematic Review of Methimazole in Graves' Disease Management: Treatment Variations and Efficacy Outcomes

    Dec 1, 2024, 00:00

  • P43 Health-Related Quality of Life in People Living With Dementia: Over and Underestimation of Proxy-Ratings

    Dec 1, 2024, 00:00

  • EE530 Cost-Effectiveness of Orphan Medicines for the Management of Spinal Muscular Atrophy: Thinking Outside the Box

    Dec 1, 2024, 00:00

  • CO81 Pregabalin Utilization and Side Effects Among Hemodialysis Patients Diagnosed With Pruritus or Neuropathic Pain in US Claims Data

    Dec 1, 2024, 00:00

  • EE733 Budget Impact Analysis of Metreleptin in Patients With Lipodystrophy in Saudi Arabia

    Dec 1, 2024, 00:00

  • EE245 Economic Burden in Patients With Chronic Myeloid Leukemia in Early Lines of Therapy: A Literature Review

    Dec 1, 2024, 00:00

  • EE610 Age-Targeted Vaccination for Reducing Clostridioides Difficile Infection in England: A Coupled Mathematical-Economic Modeling Analysis

    Dec 1, 2024, 00:00

  • EE339 Cost and Healthcare Resource Utilization (HRU) Among Patients Living with Angelman Syndrome (AS): A Systematic Review

    Dec 1, 2024, 00:00

  • HTA29 The Use of Real-World Evidence in NICE Health Technology Appraisals: A Quantitative Review of Submissions to NICE Between 2022 and 2024

    Dec 1, 2024, 00:00

  • HSD49 Neoadjuvant Immunotherapy in Patients With Early-Stage, High-Risk, ER+/HER2– Breast Cancer: Physician Practices, Therapy Choice, and Barriers Among US Oncologists

    Dec 1, 2024, 00:00

  • EE492 Cost-Effectiveness of CDK4/6 Inhibitors (CDK4/6i) in First- vs Second-Line for Advanced Breast Cancer in the Phase 3 SONIA Trial (BOOG 2017-03)

    Dec 1, 2024, 00:00

  • EE377 Cost-Effectiveness of Nirmatrelvir/Ritonavir in COVID-19 Patients at High-Risk for Progression in Spain

    Dec 1, 2024, 00:00

  • CO90 Matching-Adjusted Indirect Comparison of Efficacy and Safety for Lebrikizumab, Dupilumab, and Tralokinumab in Patients With Moderate-to-Severe Atopic Dermatitis Not Adequately Controlled or Non-eligible for Cyclosporine

    Dec 1, 2024, 00:00

  • HSD122 Burden of Low Molecular Weight Heparin Switching in the UK and Canada

    Dec 1, 2024, 00:00

  • EE582 Approaches to Discussions on Confidential Pricing Whilst Enabling Analysis of “True” Budget Impact

    Dec 1, 2024, 00:00

  • CO131 Comparative Efficacy of Elafibranor and Seladelpar in Patients With Primary Biliary Cholangitis: A Network Meta-Analysis

    Dec 1, 2024, 00:00

  • EPH69 Analysis of Influenza Vaccination Coverage and Vaccine Effectiveness in Population Aged 65 and Over in Ambulatory Medicine in France From 2016 to 2019: A Study Based on Real-World Data

    Dec 1, 2024, 00:00

  • EE698 Real-World Impact of Immunotherapy on Survival and Hospital Costs in Advanced/Metastatic Lung Cancer: A Retrospective Analysis From the French Health Data System

    Dec 1, 2024, 00:00

  • EE614 Are Different Generations of Ceramic-on-Ceramic Implants More Cost-Effective Than Metal-on-Polyethylene Implants in Primary Total Hip Arthroplasty?

    Dec 1, 2024, 00:00

  • EE484 Evaluating the Cost-Effectiveness of Dabrafenib and Trametinib for the Treatment of Pediatric Patients With Relapsed or Refractory High-Grade Glioma in England and Wales

    Dec 1, 2024, 00:00

  • EPH259 Mortality in People Diagnosed With Progressive Multifocal Leukoencephalopathy: A Systematic Literature Review

    Dec 1, 2024, 00:00

  • EE674 Cost-Effectiveness of Pemigatinib for Patients With Advanced Intrahepatic Cholangiocarcinoma and FGFR2 Fusions/Rearrangements: 2024 FIGHT-202 Trial Final Results

    Dec 1, 2024, 00:00

  • EPH197 Risk of Drug-Induced Interstitial Lung Disease in Korean Patients With Lung Cancer: A Nested Case-Control Study

    Dec 1, 2024, 00:00

  • EE613 Cost-Effectiveness Analysis of RSVPreF3 OA Vaccine in Sweden for Adults Aged ≥ 60 Years

    Dec 1, 2024, 00:00

  • EPH205 Overall Survival in Individuals Diagnosed With Progressive Multifocal Leukoencephalopathy

    Dec 1, 2024, 00:00

  • HTA168 Level of ICER of Health Economic Assessment in France in 2023

    Dec 1, 2024, 00:00

  • EE598 The Economic Burden of HER2+ Breast Cancer and the Targeted Therapies Epidemiological Economic Impact in the Anita Moreno Hospital of Panama

    Dec 1, 2024, 00:00

  • EE554 Global Dynamics of Drug Pricing: Analyzing the Influence of Emerging Countries on Pricing Strategies in Developed Nations

    Dec 1, 2024, 00:00

  • CO23 An Indirect Comparison of Polihexanide 0.08% Versus Currently Used Treatments for Acanthamoeba Keratitis

    Dec 1, 2024, 00:00

  • P46 Comparing Data Collection Methods: Health Care Professional Survey-Based Chart Audit Versus Automated Electronic Health Record Databases in Multicountry Drug Utilization Studies

    Dec 1, 2024, 00:00

  • EE685 What Is the Real Price of Switching Medical Technologies? Evaluation of Financial and Value-Based Aspects: The Case for Dialysis

    Dec 1, 2024, 00:00

  • EE307 Comparing Ancillary Services Associated With Subcutaneous Versus Intravenous Medication Administration

    Dec 1, 2024, 00:00

  • EPH65 Analyzing the Effect of Meteorological Factors on Stroke Inciden The Case of Hungary

    Dec 1, 2024, 00:00

  • HSD72 Real World Evidence on Impact of Clinical Decision Support System (CDSS) Alerts on General Practitioners Adherence to the New Gastro-Oesophageal Reflux Disease Treatment Guidelines in German Primary Care Settings

    Dec 1, 2024, 00:00

  • EE720 Cost-Effectiveness of Faricimab in Canada for the Treatment of Patients With Macular Edema Secondary to Retinal Vein Occlusion

    Dec 1, 2024, 00:00

  • EE620 Cost-Effectiveness of PCV15 in the Pediatric Population for Preventing Pneumococcal Disease in France

    Dec 1, 2024, 00:00

  • EE272 Using Structured Expert Elicitation in Cost-Effectiveness Analysis: An Exploratory Case Evaluating Selpercatinib for Thyroid Cancer in Norway

    Dec 1, 2024, 00:00

  • HSD45 The Dental Care Needs and the Government's Intervention Service in People With Special Needs in Taiwan

    Dec 1, 2024, 00:00

  • EE682 Carbetocin for the Prevention of Postpartum Hemorrhage Due to Uterine Atony Following Vaginal Delivery: A Retrospective Cost-Benefit Analysis Based on Clinical Experience from Polish Medical Centers

    Dec 1, 2024, 00:00

  • EE817 Exploring the Impact of the New NICE Disease Severity Modifier on HTA Oncology Submissions: A Retrospective Analysis of Technology Appraisals

    Dec 1, 2024, 00:00

  • HTA87 Exploring the Effects of the European Union (EU) Joint Health Technology Assessment (HTA) on the Launch Sequencing of New Drugs and Identifying Opportunities to Improve the Availability of Reimbursed Medicines in Europe

    Dec 1, 2024, 00:00

  • HPR138 Analysis of Health Technology Assessments of Lung Cancer Therapies in Germany in the Last Decade: Is There an Association Between Added Benefit Ratings and Negotiated Reimbursement Prices?

    Dec 1, 2024, 00:00

  • EPH288 Characteristics of NASH Patients Who Develop Hepatocellular Carcinoma (HCC) With and Without a Corresponding Cirrhosis Diagnosis

    Dec 1, 2024, 00:00

  • EPH255 Understanding Alopecia Areata: An Estimation of the Portuguese Epidemiology Data

    Dec 1, 2024, 00:00

  • PT26 From Clinical Assessment to Drug Reimbursement in Spain: Current Timelines and Potential Impact From the Joint Clinical Assessment

    Dec 1, 2024, 00:00

  • EE365 Economic Evaluation of Transcatheter Aortic Valve Implantation (TAVI) Relative to Other Interventions in Cardiovascular and Oncology Disease Areas: A Targeted Literature Review

    Dec 1, 2024, 00:00

  • HPR59 Managed Access Protocols As an Innovative Approach to Enabling Access to High-Cost Orphan Medicines: The Irish Experience

    Dec 1, 2024, 00:00

  • EE544 Early Cost-Effectiveness Analysis of AI-Enhanced Remote Monitoring Solutions for Timely Detection of Advanced Parkinson's Disease in Finland

    Dec 1, 2024, 00:00

  • CO103 Characteristics of Patients With Ehlers-Danlos Syndromes (EDS): Analysis of US Real-World Data

    Dec 1, 2024, 00:00

  • EE841 Economic Evaluations of AI-Assisted Technology in Healthcare: How Are We Assessing the Cost-Effectiveness of These New Therapies?

    Dec 1, 2024, 00:00

  • HPR84 The Price Negotiation Phase of the Reimbursement Process in Ireland

    Dec 1, 2024, 00:00

  • HTA162 Development of an NCPE-Adjusted Base Case: Assessment and Adjustment of Applicant Base Cases From the Perspective of a Health Technology Assessment Body

    Dec 1, 2024, 00:00

  • CO6 Projected Public Health Benefits of Increasing Vaccine Coverage for COVID-19 Among Adults ≥ 50 Years of Age in the United States

    Dec 1, 2024, 00:00

  • HTA79 A Framework for Early Health Technology Assessments of Screening Methods: A Case Study by Evaluating Fracture Risk in Community Dwelling Older Adults

    Dec 1, 2024, 00:00

  • HPR245 Baseline Characteristics of Patients Approved for Reimbursement of Liraglutide (Saxenda®) for Weight Management Under a Managed Access Protocol in Ireland

    Dec 1, 2024, 00:00

  • HTA132 One for All? Exploring the Need for Country Specific Value Sets for Preference-Based Measures of Health

    Dec 1, 2024, 00:00

  • HPR113 Social Determinants of Health and Use of Glucagon-like Peptide-1 Receptor Agonists in the Pediatric Population

    Dec 1, 2024, 00:00

  • HSD81 Integrating IPU Principles for Improved Lung Cancer Care at an Oncology Center

    Dec 1, 2024, 00:00

  • HPR68 How to Overcome the Remaining Challenges for Successful Implementation of the EU HTA Regulation: Key Insights From the 2023 European Access Academy Spring Convention and Survey

    Dec 1, 2024, 00:00

  • HTA109 European Joint Clinical Assessment: How Many PICOs Are Too Many?

    Dec 1, 2024, 00:00

  • HPR7 The Discrepancy in Real-World Evidence of New Drug Expenditure Between Actual and Estimated Figures From Manufacturers and Government Agencies in Taiwan

    Dec 1, 2024, 00:00

  • EPH105 Prevalence of Metabolic and Micro-Vascular Complications Among English Adult Patients With Type 1 Diabetes Who Were Initiated on Basal Insulin Analogues Between 2014 and 2019: A Population-Based Retrospective Cohort Study

    Dec 1, 2024, 00:00

  • The Impact of Additive Population(s), Intervention, Comparator(s), and Outcomes in a European Joint Clinical Health Technology Assessment

    Dec 1, 2024, 00:00

  • EE314 A Cost-Utility Analysis in Patients With Inflammatory Bowel Disease and Iron Deficiency Anemia in the Netherlands: Reduced Hypophosphatemia and Fracture Incidence With Ferric Derisomaltose Versus Ferric Carboxymaltose

    Dec 1, 2024, 00:00

  • EE316 An Iterative Survey of Phenylketonuria (PKU) Medical Experts to Inform Health Economic Modeling Methods

    Dec 1, 2024, 00:00

  • HTA111 EU Joint Clinical Assessment (JCA): Uncertain Impact on German Amnog Timelines and Potential Delays

    Dec 1, 2024, 00:00

  • HTA48 Evaluating the Relevance of Conditional Marketing Authorization for Successful HTA Outcomes in France

    Dec 1, 2024, 00:00

  • EE483 The Contribution of Innovative Drugs and the National Reimbursement Drug List to Human and Physical Capital in the Social Economy: A Case of Blood Cancer in China

    Dec 1, 2024, 00:00

  • HPR204 Early Access Programmes in Europe Versus Key Markets in Other Regions: An In-Depth Comparison

    Dec 1, 2024, 00:00

  • EE270 Cost-Effectiveness Evaluation of Sequential Treatment Stategies for Treatment Naïve Patients With BRAF Mutant Metastatic Melanoma in UK: Nivolumab Plus Ipilimumab First-Line Versus Dabrafenib Plus Trametinib First-Line

    Dec 1, 2024, 00:00

  • CO38 Burden and Trends of COPD Exacerbations in France Before and During the Pandemic

    Dec 1, 2024, 00:00

  • EPH170 Burden of Severe ANCA Associated Vasculitis in Australia via Real-World Usage of Rituximab

    Dec 1, 2024, 00:00

  • P47 Evaluation of Natural Language Processing (NLP) on Electronic Medical Records: A Proof of Concept on Chronic Graft Versus Host Disease (cGVHD) in France

    Dec 1, 2024, 00:00

  • EPH173 A Visual Representation of the Observational Study of Extended Adjuvant Neratinib in HER2+ Early Breast Cancer (EBC) in the Context of the European Early Access Program (EAP): Near Study Final Results

    Dec 1, 2024, 00:00

  • EPH14 Gastrointestinal Endoscopy Volume, Efficiency, and Safety Issues: A Case Report

    Dec 1, 2024, 00:00

  • EE516 Non-QALY Benefits of Treatments of Alzheimer's Disease and Related Dementias

    Dec 1, 2024, 00:00

  • HPR122 Innovative Approaches to Broaden Access in Chronic-High Prevalent Diseases (Obesity)

    Dec 1, 2024, 00:00

  • EPH16 New Onset Depression During Pregnancy in Commercially-Insured and Medicaid-Insured Pregnancies in the United States

    Dec 1, 2024, 00:00

  • EPH66 How Real Is Your Real-World Evidence (RWE)? Demonstration of the Need for Comprehensive Real-World Data (RWD) to Examine Patient Burden and Disease Journey in Patients With Sickle Cell Disease (SCD) in the United States (US)

    Dec 1, 2024, 00:00

  • HTA151 Rapid Review of Published Economic Evaluations of Larotrectinib and Entrectinib: Current Practices to Overcome Challenges in Health Technology Assessment of Tumor-Agnostic Treatments

    Dec 1, 2024, 00:00

  • HTA53 Trends Underlying Positive and Negative Decision-Making for New Oncology Treatments Appraised by the National Institute for Health and Care Excellence (NICE) in 2023

    Dec 1, 2024, 00:00

  • EE407 Budget Impact Analysis of Paliperidone Palmitate in Chronic Schizophrenia in the Mental Health Secretariat-Egyptian Ministry of Health

    Dec 1, 2024, 00:00

  • EPH51 Evaluation of US/European Deprivation Indices Applications in Oncological, Health Economics, and Outcomes Research (HEOR) Studies

    Dec 1, 2024, 00:00

  • EE517 Cell-Free DNA Epigenomic-Based Test Is Predicted to Be Cost-Effective to Manage New-Onset Type 2 Diabetes Patients for Risk of Pancreatic Cancer

    Dec 1, 2024, 00:00

  • Rare Diseases: Economic Evaluation and Policy Considerations [Editor's Choice]

    Dec 1, 2024, 00:00

  • HPR166 Understanding Differences in Pharmaceutical Products Based on Price Publication Status

    Dec 1, 2024, 00:00

  • EPH113 Impact of Indoor Air Pollution on Health in Low-to-Middle Income Countries

    Dec 1, 2024, 00:00

  • EPH83 Public Health Impact of a Simplified Booster Vaccine Schedule Against Tick-Borne Encephalitis (TBE) in Austria: A Modeling Analysis

    Dec 1, 2024, 00:00

  • EPH217 Prescription Medication Patterns and Polypharmacy Among Chinese Patients With Diabetes: A Retrospective Cohort Study

    Dec 1, 2024, 00:00

  • EE313 Model-Based Assessment of the Costs and Benefits of Lung Cancer Screening in the Czech Republic Before Introduction of the National Pilot Program

    Dec 1, 2024, 00:00

  • EE669 Analysis of the Costs and Carbon Footprint Associated With Reusable Flexible Cystoscopes: Implications for the Utilization of Single-Use Digital Flexible Cystoscopes

    Dec 1, 2024, 00:00

  • EE529 Human Papilloma Virus in Italy: Cost of Illness and Potential Savings Due to HPV9 Primary Prevention in Adult Women

    Dec 1, 2024, 00:00

  • HPR187 Injectable Oncology Therapies: Benchmarking Gross and Net Price Differentials in Europe vs US

    Dec 1, 2024, 00:00

  • HPR116 Expediting Reimbursement and Access for Novel Drug Indications in Europe: A Case Study on Glucagon-Like Peptide 1 (GLP-1) Agonists

    Dec 1, 2024, 00:00

  • HTA74 Incorporating Environmental Sustainability Into Health Technology Assessments: Two Adapted Cost-Utility Analyses (CUA) of Insulin Icodec Versus Degludec for Type 2 Diabetes (T2D) Management in England

    Dec 1, 2024, 00:00

  • HTA31 Insulin Analogs in Type 1 Diabetes Treatment: Is There Access After Unified Health System (SUS) Incorporation?

    Dec 1, 2024, 00:00

  • EE752 Avoided Costs Attributable to the Effectiveness of Optimal Management of Lipid-Lowering Agents in a Cohort of Patients at Cardiovascular Risk in the Colombian Caribbean

    Dec 1, 2024, 00:00

  • EPH212 Prevalence of Pulmonary Embolism Among Medicare Enrollees: A Six-Year Perspective

    Dec 1, 2024, 00:00

  • HTA96 The Increasing Use of Real-World Data in Health Technology Appraisals of Oncology Therapies: A Systematic Review

    Dec 1, 2024, 00:00

  • EE591 Global Health Economic Burden of Angelman Syndrome: A Systematic Literature Review

    Dec 1, 2024, 00:00

  • CO65 Indirect Treatment Comparison of Biologic Treatments in Adolescents With Moderate to Severe Atopic Dermatitis: A Systematic Literature Review and Network Meta Analysis

    Dec 1, 2024, 00:00

  • EPH266 An Economic Model to Assess the Costs and Benefits of Workplace Mental Wellbeing Interventions: A Flexible Tool for Employers and Decision Makers

    Dec 1, 2024, 00:00

  • HTA65 Exploring PICO Variations in Relapsed or Refractory DLBCL in the Context of the European Joint Clinical Assessment

    Dec 1, 2024, 00:00

  • HSD93 The Diagnosis and Management of Uncontrolled and Treatment-Resistant Hypertension: A Targeted Literature Review of Eight Countries Clinical Practice Guidelines

    Dec 1, 2024, 00:00

  • Toward Patient-Centered Drug Approval for Treatment of Rare Diseases

    Dec 1, 2024, 00:00

  • EE251 Economic Evaluation and Budget Impact Analysis of a Novel Monotherapy for Advanced Melanoma With Low Pd-L1 Expression in Bulgaria

    Dec 1, 2024, 00:00

  • HPR205 An International Mapping Review of Medicines Approvals and Access to Innovative Technologies for the United Kingdom (UK): A Retrospective Analysis

    Dec 1, 2024, 00:00

  • HSD70 Budget Impact of a Minimally Invasive Surgical Treatment for Benign Prostatic Hyperplasia in Australian Public Hospitals

    Dec 1, 2024, 00:00

  • EE532 Budget Impact Analyses of Hemoglobin a1C and Lipid Panel Point-of-Care Testing With Afinion™ 2 in Italy and Canada

    Dec 1, 2024, 00:00

  • HTA148 Off-Label Comparators in Health Technology Assessment Decision Making in Portugal

    Dec 1, 2024, 00:00

  • EE725 Cost-Effectiveness of Linzagolix for Uterine Fibroids in Australia: A Healthcare Payer and Societal Perspective

    Dec 1, 2024, 00:00

  • EPH11 Burden of HPV-Associated Cancers in Mexico From 2011-2019

    Dec 1, 2024, 00:00

  • EE443 Cost-Effectiveness Analysis of RSVPreF3 OA Vaccine in Greece for Adults Aged ≥60 Years

    Dec 1, 2024, 00:00

  • EPH12 Hospitalization Rates of HPV-Associated Cancers in Brazil From 2011-2019

    Dec 1, 2024, 00:00

  • EPH60 Temporal Trends in Vaccination and Antibiotic Use Among Young Children in the United States, 2000-2019

    Dec 1, 2024, 00:00

  • HSD77 From Centralized Manufacturing to Bedside Production: Advancing CAR T-Cell Therapies Through Collaborative Innovation

    Dec 1, 2024, 00:00

  • HTA51 Health Equity and HTA: The HTA Agencies Are Asking for Equity Data, But Are They Using It?

    Dec 1, 2024, 00:00

  • CO30 Real-World Treatment Patterns in Patients With Biochemical Recurrence After Local Therapy for Prostate Cancer: Retrospective Analysis of a Large US Database

    Dec 1, 2024, 00:00

  • HSD2 Optimizing Radiotherapy Utilization Through Systematic and Synergistic Real-Time Monitoring

    Dec 1, 2024, 00:00

  • EE583 Economic Burden of Dedifferentiated Liposarcoma in Metastatic and Non-Metastatic Patients: A Retrospective Observational Study Using Danish Population-Based Register Data

    Dec 1, 2024, 00:00

  • HTA195 Assessment of Time to HTA Outcome for Novel Oncology Combinations and Decision Drivers Across UK and Europe

    Dec 1, 2024, 00:00

  • HPR154 Comparison of Generic Drug Prices Between China and the United States

    Dec 1, 2024, 00:00

  • EPH279 Trends in Epidemiology and Mortality of Patients With Pancreatic Cancer in Germany: A Retrospective Study Using German Claims Data

    Dec 1, 2024, 00:00

  • EE486 Budget-Impact Model for the Use of Continuous Monitoring of Patient Vital Signs in US Hospital Medical-Surgical Floors

    Dec 1, 2024, 00:00

  • CO115 LDL-C Goals Attainment in Patients at Very High Cardiovascular Risk: A Multicentric RWE Evaluation in Colombia

    Dec 1, 2024, 00:00

  • HTA138 NICE vs SMC: Reimbursement Differences for Non-Oncology Orphan Drugs

    Dec 1, 2024, 00:00

  • EPH62 Effects of Shift Work on Food Choice Habits and Stress Levels of Nurses and Paramedics: A Cross-Sectional Study

    Dec 1, 2024, 00:00

  • EE795 Healthcare Resource Utilization and Costs Associated With Infectious Mononucleosis in the United States

    Dec 1, 2024, 00:00

  • EE693 Cost-Effectiveness of Atidarsagene Autotemcel (ARSA-CEL) Gene Therapy for Treating Metachromatic Leukodystrophy (MLD) in Ireland, Belgium, and the Netherlands As a Part of the Beneluxa Initiative

    Dec 1, 2024, 00:00

  • HSD127 Real-World Patterns of Tyrosine Kinase Inhibitor (TKI) Discontinuation and Reinitiation in Chronic Myeloid Leukemia (CML) Patients in the United States

    Dec 1, 2024, 00:00

  • EE535 Cost-Utility Analysis of an Advanced Hybrid Closed-Loop System vs Multiple Daily Injection Therapy With Intermittently Scanned Continuous Glucose Monitoring in People With Type 1 Diabetes and Above-Target HBA1C in France

    Dec 1, 2024, 00:00

  • EPH123 Characterization of Trabeculectomy Use and the Impact of COVID-19 in Medicare Beneficiaries With Primary Glaucoma by US Region

    Dec 1, 2024, 00:00

  • EE745 Health Economic Modelling of Prediabetes Progression and Type 2 Diabetes Risk Based on Published Data From a Swedish Intervention Program

    Dec 1, 2024, 00:00

  • EPH19 Ovarian Cancer Age-Adjusted Mortality Rates in Chile During 2002-2019

    Dec 1, 2024, 00:00

  • EE323 Hospitalization Burden of Crohn's Disease and Ulcerative Colitis in the Middle Atlantic: A Six-Cohort Analysis of Pooled National In-Patient Data (2016-2020)

    Dec 1, 2024, 00:00

  • CO113 Association of Viral Infections in Alzheimer's Disease Among Patients With Mild Cognitive Impairment in Korea

    Dec 1, 2024, 00:00

  • HPR170 High-Cost Medicines: Perceptions and Definitions Present in Brazilian Scientific and Academic Production on Health Litigation

    Dec 1, 2024, 00:00

  • CO16 Savings Associated With the Optimization of Pharmacological Therapy in Patients With Chronic Respiratory Pathologies

    Dec 1, 2024, 00:00

  • HSD112 Transforming Healthcare Access: Empowering Chinese Patients Through Generative AI Across City Tiers and Age Groups

    Dec 1, 2024, 00:00

  • EE579 Budget Impact Analysis of Incorporating PlGF in Preeclampsia Screening in Catalonia

    Dec 1, 2024, 00:00

  • HPR121 Characteristics of High-Cost Medicines in the Context of Health Judicialization in Brazil: A Scoping Review

    Dec 1, 2024, 00:00

  • HPR146 Did the EMA and FDA Accelerated Approval Pathways Reverse the Drought in Novel Anti-Infectives?

    Dec 1, 2024, 00:00

  • EE617 An Italian Pharmacoutilization Analysis in Patients With Hemophilia A With and Without Inhibitors After Switching to Emicizumab

    Dec 1, 2024, 00:00

  • HPR197 The Reimbursable Rebate Difference (RRD), an Incentive for Hospitals in France to Negotiate Drug Prices Delivered to Outpatients: What Are the Determinants and Dynamics?

    Dec 1, 2024, 00:00

  • EE404 Cost-Effectiveness of Rapid Direct Multiplex PCR Test for Diagnosing Meningitis and Encephalitis From the Brazilian Public Perspective

    Dec 1, 2024, 00:00

  • EE277 Cost of Stroke in Latin America: A Multicentric Time-Driven Activity-Based Costing Study

    Dec 1, 2024, 00:00

  • CO25 PRO-WAVE1: Monitoring Patient Reported Outcomes (PROs) in Prostate Cancer Through Wave Health: A Novel ePRO Health Platform

    Dec 1, 2024, 00:00

  • EPH204 Health Disparities in Postpartum Complications by Race and Ethnicity: A Marketscan by Merative Retrospective Cohort Analysis

    Dec 1, 2024, 00:00

  • HPR171 Estimating the Impacts of Government-Mandated Price Reductions on Indication Expansion for Launched Drugs: A Real-World Study

    Dec 1, 2024, 00:00

  • HTA150 Analysis of the Change of the Added Benefit and Respective Reasons in Renewed Regular Benefit Assessments of Orphan Drugs Due to Exceeding the Sales Threshold in Germany: Update Until Mai 2024

    Dec 1, 2024, 00:00

  • HPR74 Enhancing the Acceptance of Externally Controlled Trials (ECTs) in the German HTA System: Analysis of Guidance Documents From Other Countries

    Dec 1, 2024, 00:00

  • EPH2 Costs of Hospitalizations Due to Respiratory Syncytial Virus (RSV) Illness Among Children and Adolescents in Ontario, Canada

    Dec 1, 2024, 00:00

  • HPR240 A Rapid Review of Key Challenges and Success Factors in Implementing Managed Entry Agreements for Pharmaceuticals: Lessons for Greece

    Dec 1, 2024, 00:00

  • HTA26 Determining the Value Contribution of Trifluridine/Tipiracil With Bevacizumab for the Treatment of Metastatic Colorectal Cancer in Catalonia Using a Multi-Criteria Decision Analysis

    Dec 1, 2024, 00:00

  • CO83 Utilization and Outcomes of Extracorporeal Membrane Oxygenation in China and Scandinavia: A Systemic Literature Review

    Dec 1, 2024, 00:00

  • EE820 Cost-Utility Analysis of an All-Preterm Infant Immunization With Nirsevimab Against Respiratory Syncytial Virus (RSV): Associated Disease at the Brazilian Private Healthcare System

    Dec 1, 2024, 00:00

  • HTA155 Health Technology Assessment (HTA) of Respiratory Biologics: Highlighting the Differences in Value Assessment of Asthma Interventions Globally

    Dec 1, 2024, 00:00

  • CO29 An Ensemble Approach to Predicting Overall Survival (OS) Benefit Jointly From Multiple Surrogate Endpoints (SE) in Oncology: A Case Study in Previously Untreated Metastatic Melanoma

    Dec 1, 2024, 00:00

  • EE476 Cost-Minimization and Budget Impact Analysis of Abiraterone (Tarosyn® and Avitosyn®) as Second Line Treatment for Metastatic Prostate Cancer Resistant to Castration in Mexico

    Dec 1, 2024, 00:00

  • EE498 Cost-Effectiveness of a Photopethysmographic Test for Screening for Atrial Fibrillation in Three European Countries Including Indirect Costs

    Dec 1, 2024, 00:00

  • EPH52 Challenges of Missing Specific Disease Codes: Estimating Incidence and Prevalence of Immunoglobulin A Nephropathy (IgAN) Using Health Insurance Claims Data

    Dec 1, 2024, 00:00

  • EE468 A Systematic Review of Health Economic Evaluation on Therapies for the Treatment of Inherited Retinal Diseases: A Quality Evaluation

    Dec 1, 2024, 00:00

  • EE540 Cost-Effectiveness of Next Generation Sequencing to Select Microsatellite Stable/Mismatch Repair Proficient Metastatic Colorectal Cancer Patients for Immune Checkpoint Inhibitor Therapy

    Dec 1, 2024, 00:00

  • HPR27 Guideline for Health Economic Evaluation of Medicines: A Proposal by the Advisory Committee for Financing Pharmaceutical Benefits (CAPF) in the Spanish National Health System

    Dec 1, 2024, 00:00

  • CO39 Efficacy and Quality of Life Benefits of Biologics in Chronic Rhinosinusitis With Nasal Polyposis: A Systematic Literature Review and Meta-Analysis

    Dec 1, 2024, 00:00

  • EPH102 Healthcare Utilization Among RTT Patients With Aspiration and Epilepsy in a Center of Excellence Medical Center in the United States

    Dec 1, 2024, 00:00

  • PT20 Impact of Huge-Seller Repricing on Price Trend for Reimbursable Cancer Drugs in Japan

    Dec 1, 2024, 00:00

  • EE536 The Benefit of Introducing Remimazolam for General Anesthesia in Belgian Clinical Practice

    Dec 1, 2024, 00:00

  • HPR46 Exploring Managed Entry Agreements: A Scoping Review of Approaches, Considerations, and Country-Specific Approaches

    Dec 1, 2024, 00:00

  • EE281 Cost-Effectiveness Analysis of Bimekizumab in Patients With Axial Spondyloarthritis (AXSPA) in Greece

    Dec 1, 2024, 00:00

  • HPR142 Measuring Impact of HTA on Patient Access to New Medicines in NHS England: A Comparison of Public Health Insurance Funding Restrictions and Patient Uptake for New Medicines across England, France, Germany, and the United States

    Dec 1, 2024, 00:00

  • EE602 Is Universal Screening for Hypothyroidism in Pregnant Women a Cost-Effective Strategy in Indonesia and Mexico?

    Dec 1, 2024, 00:00

  • CO55 Estimation of the Effect of Inclisiran in LDL-C Reduction in a Regional Portuguese Population

    Dec 1, 2024, 00:00

  • EE504 Leveraging Large Language Models for Conceptualizing Health Economic Models: A Feasibility Study in Oncology

    Dec 1, 2024, 00:00

  • HTA144 Is Pediatric Indication an Implicit Driver of the French HTA Appraisal Outcomes?

    Dec 1, 2024, 00:00

  • EE832 The Lifetime Return on Investment of Measles, Mumps, and Rubella Vaccination in Belgium and Poland

    Dec 1, 2024, 00:00

  • HTA105 Has the NICE Methods and Processes Update Accelerated Access to Rare Disease Technologies Routed Via the Single Technology Appraisal (STA) Pathway?

    Dec 1, 2024, 00:00

  • EE714 Identifying Patients With High Economic Burden Using Real-World Data: The Case of Myasthenia Gravis (MG)

    Dec 1, 2024, 00:00

  • EE249 The Hidden Burden of Migraine: Analysis Using a Fiscal Framework in Colombia

    Dec 1, 2024, 00:00

  • EPH28 Revolutionizing Systematic Reviews: The Precision of LLMS in Screening Observational Studies

    Dec 1, 2024, 00:00

  • EE827 Do Subcutaneous Treatments Provide Most Cost Savings Than Intravenous Treatments in Breast Cancer: A Literature Review

    Dec 1, 2024, 00:00

  • HPR133 The Global Impact of EU HTA: Insights From 13 Non-EU Countries

    Dec 1, 2024, 00:00

  • HPR152 A Comparison of the Acceptability of Evidence in the New Joint Clinical Assessment and Nine European Union Countries

    Dec 1, 2024, 00:00

  • EE810 Cost-Utility Analysis of Empagliflozin on Chronic Kidney Disease Progression in Patients With Chronic Kidney Disease in Thailand

    Dec 1, 2024, 00:00

  • HPR124 Where HTA Meets Physics: Motion and Acceleration in Access to Innovative Medicines

    Dec 1, 2024, 00:00

  • HTA72 Evolving National Health Technology Assessment (HTA) Frameworks in Theory Versus Practice in the Asia-Pacific (APAC) Region: A Targeted Literature HTA Review Focusing on Australia, Japan, and Taiwan

    Dec 1, 2024, 00:00

  • EE334 Use of Disease Analogues to Inform Health-Economic Parameters for Economic Evaluations of Rare Diseases: A Case-Study of Multiple System Atrophy

    Dec 1, 2024, 00:00

  • EE400 Cost-Effectiveness of Avacopan for the Treatment of Granulomatosis with Polyangiitis or Microscopic Polyangiitis in Adult Patients in Austria

    Dec 1, 2024, 00:00

  • EPH216 Prevalence of Obesity and Overweight in the Maghreb Region: Systematic Review and Meta-Analysis

    Dec 1, 2024, 00:00

  • CO13 Impact on Health Outcomes and Productive Work of Anti-PD-(L)1 Inhibitors to Treat Early-Stage Cancers in England

    Dec 1, 2024, 00:00

  • HTA118 Benefit vs Uncertainties: The Potential Impact of Joint Clinical Assessment (JCA) on Market Access and Reimbursement of Novel Drugs

    Dec 1, 2024, 00:00

  • EE821 Effect of Socioeconomic Status on the Direct Costs of Lupus Nephritis in Colombian Patients

    Dec 1, 2024, 00:00

  • EPH149 COVID-19 Cases and Deaths by Social Vulnerability in Chicago Community Areas

    Dec 1, 2024, 00:00

  • EE623 Budget Impact Analysis of Empagliflozin for Adults With Chronic Kidney Disease (CKD) in Greece

    Dec 1, 2024, 00:00

  • HSD65 Optimizing Management and Outcomes of Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS) in Spain: BEWAYAPDS Project

    Dec 1, 2024, 00:00

  • EE436 Investigation of the Economic Burden of Constipation in Patients With Chronic Musculoskeletal Pain

    Dec 1, 2024, 00:00

  • EE488 The Potential Public Health Impact of New Immunization Strategies for the Prevention of RSV in Children in Panama

    Dec 1, 2024, 00:00

  • EE345 Development of the Piccoteam Reference Case for Economic Evaluation of Precision Medicine

    Dec 1, 2024, 00:00

  • HPR50 The Impact of First Generic Entrance on Public Spending and Medicines Cost: A Case Study in Bulgaria

    Dec 1, 2024, 00:00

  • EE445 Evaluating the Cost-Effectiveness of Metformin in Prediabetes Management: A Markov Model Analysis Combining Clinical and Real-World Data

    Dec 1, 2024, 00:00

  • HTA128 Kaleidoscope (QALY in Scope): A Conceptual Framework for Contextualizing Value via Dynamic Cost-Effectiveness Threshold

    Dec 1, 2024, 00:00

  • CO134 The Impact of Approved Anti-Obesity Medications on the Incidence of Obstructive Sleep Apnea, Healthcare Resource Utilization and Costs Among Patients, with Obesity: A Retrospective Cohort Study

    Dec 1, 2024, 00:00

  • EE723 Healthcare Resource Utilization Among Patients With Sickle Cell Disease With Recurrent Vaso-Occlusive Crises in the Netherlands

    Dec 1, 2024, 00:00

  • EPH240 Adapted Targeted Literature Review (ATLR) for Landscaping Trends in Pregnancy Post Authorization Safety Studies (PASS)

    Dec 1, 2024, 00:00

  • HPR92 Price Analysis of Systemic Antibacterial Drugs Approved in the US (January 1980 - December 2020)

    Dec 1, 2024, 00:00

  • CO63 Clinical Meaningfulness of Improvements in Quality of Life Observed With Garadacimab Treatment in Patients Living With Hereditary Angioedema: Results From the Pivotal Phase 3 (VANGUARD) Study

    Dec 1, 2024, 00:00

  • CO107 Indirect Treatment Comparison of Efgartigimod vs Immunoglobulins in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

    Dec 1, 2024, 00:00

  • HTA5 A Review and Evaluation of Reimbursement Outcomes for Non-Orphan and Orphan Drugs in Ireland in 2023

    Dec 1, 2024, 00:00

  • EE444 Early Health Technology Assessment of Artificial Intelligence in the Intensive Care Unit: Validation of a Generic Health-Economic Model

    Dec 1, 2024, 00:00

  • EPH278 Trends in Epidemiology and Mortality of Patients With Lung Cancer in Germany: A Retrospective Study Using German Claims Data

    Dec 1, 2024, 00:00

  • PT14 Economic Evaluation of an eHealth Application Fostering Palliative Care for Cancer Patients in Greece

    Dec 1, 2024, 00:00

  • EE596 Economic Burden Due to Seasonal Influenza in Subjects Aged 50-64 in the USA

    Dec 1, 2024, 00:00

  • HTA16 When Timelines Collide: How EMA Regulatory Milestones Can Impact the JCA Process, and Implications for Manufacturers and Member States

    Dec 1, 2024, 00:00

  • HSD136 Assessing Gaps in the Timely Referral of Patients for a Rare Disease Diagnosis: A Cross-Sectional Survey of Physicians in Europe

    Dec 1, 2024, 00:00

  • EPH211 Analysis of Regional Differences in Female Infertility in Hungary in the Last Decade

    Dec 1, 2024, 00:00

  • EE379 Cost-Effectiveness Analysis of First-Trimester Ultrasound Screening for Fetal Structural Abnormalities in China

    Dec 1, 2024, 00:00

  • EE446 Health and Budget Impact of Lenacapavir for HIV Pre-Exposure Prophylaxis in South Africa, Western Kenya, and Zimbabwe: A Modeling Analysis

    Dec 1, 2024, 00:00

  • HSD36 Medical Devices Index 2023: Access and Sourcing in Portuguese Hospitals, Challenges and Opportunities

    Dec 1, 2024, 00:00

  • HPR249 Utilization and Expenditure on Sacubitril/Valsartan (Entresto®) Over a Five-Year Period Under a Reimbursement Application System in Ireland

    Dec 1, 2024, 00:00

  • EPH47 Trends in Epidemiology and Mortality of Patients With Prostate Cancer in Germany: A Retrospective Study Using German Claims Data

    Dec 1, 2024, 00:00

  • EE703 Comparison of Administrative Burden Associated With Kesimpta and Ocrevus Among Multiple Sclerosis (MS) Clinics in Canada

    Dec 1, 2024, 00:00

  • EE673 Cost-Effectiveness Analysis of ARNI Compared to ACEI Among Heart Failure Patients With Reduced Ejection Fraction in Malaysia

    Dec 1, 2024, 00:00

  • EE641 Multi-Perspective Analysis of Hospital Costs in Fran Case Study on the French System

    Dec 1, 2024, 00:00

  • CO70 A Systematic Literature Review and Feasibility Assessment for Indirect Treatment Comparison of Insulin Icodec with Other Basal Insulins in Patients With Type 2 Diabetes

    Dec 1, 2024, 00:00

  • HTA201 A Quantitative Assessment of the Economic Decision Drivers Outlined in HTA Outcomes Through Stratification and Sentiment Analysis: Evidence From Canada, England, Scotland, and Sweden

    Dec 1, 2024, 00:00

  • HPR167 Stakeholders' Perspectives on the Use of Patient Registry Data for Decision-Making on Medicines: A Cross-Sectional Survey

    Dec 1, 2024, 00:00

  • EPH179 Real-Time Identification of Infectious Disease Symptoms Through AI-Powered Text Mining From Anonymized Electronic Health Records

    Dec 1, 2024, 00:00

  • EPH144 Buzz and Bite: The Rise of Mosquito-Borne Diseases Across Europe in Recent Years

    Dec 1, 2024, 00:00

  • HTA37 Reimbursement Process of Orphan Drugs in the Czech Republic After Legislation Change

    Dec 1, 2024, 00:00

  • HPR131 Needs and Challenges of the Payor and Regulatory Community Towards Integrating Obesity Into a Chronic Care Framework

    Dec 1, 2024, 00:00

  • HTA211 Contradictory Phase in the French Economic Appraisal: Overview and Impact on CEESP Conclusions

    Dec 1, 2024, 00:00

  • HPR44 Analysis of Anatomical Therapeutic Chemical (ATC) Classification and Therapeutic Area of Orphan Medicinal Products (OMP) vs Reimbursement for These Drugs in 11 European Countries

    Dec 1, 2024, 00:00

  • EPH72 Transferability of Health Economic Eviden A Quantitative Country Comparison of Acute Respiratory Infection and Influenza-like-Illness Incidence

    Dec 1, 2024, 00:00

  • EE259 Pharmacists as Advocators for Influenza Vaccination in Elderly Patients: A Cost-Effectiveness Analysis

    Dec 1, 2024, 00:00

  • HPR53 Market Access Impact of the Russia-Ukraine War

    Dec 1, 2024, 00:00

  • EE321 Hospitalization Burden of Congenital Adrenal Hyperplasia in New England: A Six-Cohort Analysis of National In-Patient Data (2016-2020)

    Dec 1, 2024, 00:00

  • HPR221 Revisiting Healthcare Resource Allocation for Immunotherapeutic Treatments in Cancer

    Dec 1, 2024, 00:00

  • HTA22 Are NICE Methods Appropriate for Rare Diseases That Do Not Meet the HST Criteria?

    Dec 1, 2024, 00:00

  • EE374 Transcatheter Aortic Valve Implantation vs Surgery in Symptomatic Severe Aortic Stenosis Patients at Low Surgical Mortality Risk in Belgium: An Updated Cost-Utility Analysis Based on the 5-Year Data From the Partner 3 Trial

    Dec 1, 2024, 00:00

  • HTA45 Defining Value in the Mental Illness Spa Is Caregiver Burden Considered in Health Technology Assessments of Treatments for Depression and Schizophrenia?

    Dec 1, 2024, 00:00

  • HTA117 Sentiment Analysis of Clinical Evaluations in HTA: Evidence From Canada, England, Scotland, Sweden, France, and Germany

    Dec 1, 2024, 00:00

  • EE384 The Economic Impact of Neovascular Age-Related Macular Degeneration (nAMD), Diabetic Retinopathy (DR), and Diabetic Macular Edema (DME): A Systematic Literature Review of the Emerging Literature

    Dec 1, 2024, 00:00

  • EE361 Long-Term Remission (LTR) Assumptions in Health Technology Assessments (HTAs) of Bispecific Treatments for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) Following Two or More Lines of Systemic Therapy (3L+)

    Dec 1, 2024, 00:00

  • EE513 A Systematic Review and Regression Analysis on the Value for Money of Artificial Intelligence-Empowered Precision Medicine

    Dec 1, 2024, 00:00

  • HPR3 Flat Pricing Strategies Across the 8 Major Markets

    Dec 1, 2024, 00:00

  • EPH209 Incidence of Pulmonary Nodules (PNs) in 2019 in the United States

    Dec 1, 2024, 00:00

  • HTA60 ASCO Value Framework and ESMO-Magnitude of Clinical Benefit Scale in the Incorporation of New Technologies: Case Study and Challenges in the Private Health Care System

    Dec 1, 2024, 00:00

  • EPH136 Analyzing the Effect of Body Weight on Mortality After Hip Fracture

    Dec 1, 2024, 00:00

  • EE593 The Cost-Effectiveness Outcome of Herbal Medicine (Yukgunja-tang) for the Treatment of Functional Dyspepsia Based on Randomized Controlled Trial in South Korea

    Dec 1, 2024, 00:00

  • HPR209 Pivotal Studies for Rare Diseases: Will They Better Support Market Access?

    Dec 1, 2024, 00:00

  • HPR30 Implementation of a National Value-Based Insurance Drug Formulary in the Saudi Private Health Sector

    Dec 1, 2024, 00:00

  • EE343 Cost-Effectiveness Analysis of Resmetirom for the Treatment of Adults With Noncirrhotic NASH and Moderate-to-Advanced Liver Fibrosis in the US: Integrating the Dual NASH Resolution and Fibrosis Improvement Endpoints

    Dec 1, 2024, 00:00

  • EE295 Advancing Cancer Treatment With Diagnostic Oncologic Biomarkers in Personalized Medicine in Bulgaria

    Dec 1, 2024, 00:00

  • EPH269 Changes in the Prevalence of Early Onset Dementia and Mild Cognitive Impairment in 2020-2023 Compared to 2010-2013 in German General Practices

    Dec 1, 2024, 00:00

  • HPR9 Delayed Access to Innovative Medicines in Romania: A Comprehensive Analysis of the Reimbursement Processes (2015-2024)

    Dec 1, 2024, 00:00

  • EPH146 Progression to Metastatic Breast Cancer According to Stage and Biomarker Status at Diagnosis in Denmark: A Register-Based Cohort Study

    Dec 1, 2024, 00:00

  • HSD13 Patient Characteristic, Treatment Pattern, and Healthcare Resource Utilization of Obstructive Hypertrophic Cardiomyopathy (HCM) in China on a Cardiologist Survey

    Dec 1, 2024, 00:00

  • EE394 Optimized Patient Pathway for Aortic Stenosis Patients: The Economic and Clinical Implications

    Dec 1, 2024, 00:00

  • HPR11 The Horizon of Oncology: Estimating the Impact of New EU Regulation on Health Technology Assessment for 2025-2028

    Dec 1, 2024, 00:00

  • EE341 Comparison of Markov Model and Dynamic Model in Economic Evaluations for Infectious Diseases: A Case of Bictegravir/Emtricitabine/Tenofovir Treatment-Native Adults of HIV-1 in China

    Dec 1, 2024, 00:00

  • EE279 Economic Effects of Self-Applied Patch-Based Polysomnography for Diagnostic Assessment of Obstructive Sleep Apnea in the Netherlands

    Dec 1, 2024, 00:00

  • EE611 Cost-Effectiveness of Icosapent Ethyl in Patients With Recent Acute Coronary Syndrome in Catalonia

    Dec 1, 2024, 00:00

  • HTA97 Impact of EMA's Conditional Marketing Authorizations on the Benefit Assessment Validity Period in Germany: Insights From 2017-2023

    Dec 1, 2024, 00:00

  • HTA107 Pilot Study of Digital Health Technologies for Managing Low Back Pain: Digital Therapeutics Value Assessment in South Korea

    Dec 1, 2024, 00:00

  • EPH98 Disease Burden of Respiratory Syncytial Virus in the US and Germany: A Comparative Analysis of Real-World Data Availability and Opportunities

    Dec 1, 2024, 00:00

  • CO75 A Systematic Literature Review on the Efficacy of Pharmacological Interventions in Ataxia

    Dec 1, 2024, 00:00

  • EE261 Economic Evaluation of Dupilumab Versus Standard of Care for the Treatment of Adult Patients With Moderate-to-Severe Prurigo Nodularis in the United States

    Dec 1, 2024, 00:00

  • HSD47 The Role and Importance of Evidence in US Payer Assessment and Formulary Decisions

    Dec 1, 2024, 00:00

  • P59 Measuring Health Inequality Aversion in Canada: An Equity-Efficiency Trade-Off Experiment

    Dec 1, 2024, 00:00

  • EE630 Effects and Costs of Country-Level Hepatitis C Virus Elimination in China: A Modelling Study

    Dec 1, 2024, 00:00

  • EE561 Healthcare Resource Utilization Among Patients With Transfusion-Dependent Beta-Thalassemia in the Netherlands

    Dec 1, 2024, 00:00

  • EPH260 Cost of Treatment for Mucopolysaccharidosis IV-A in a Poor Population in Colombia

    Dec 1, 2024, 00:00

  • CO116 Naldemedine Without Rescue Laxatives Versus Either Laxatives or Naloxegol in the Treatment of Opioid Induced Constipation Among Adults With Chronic Non-Cancer Pain

    Dec 1, 2024, 00:00

  • EE311 Evaluating the Cost-Effectiveness of Ruxolitinib for the Treatment of Polycythaemia Vera Patients That Are Resistant/Intolerant to Hydroxycarbamide/Hydroxyurea in England and Wales

    Dec 1, 2024, 00:00

  • EE263 Screening for Type 2 Diabetes Mellitus: A Systematic Review of Economic Evaluations

    Dec 1, 2024, 00:00

  • HSD27 Implementing Outcome Measurement for Lung Cancer Patients at an Oncology Center

    Dec 1, 2024, 00:00

  • EE756 Cost-Utility Analysis of Single-Inhaler Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate for Maintenance Therapy in Patients With Moderate-to-Severe Uncontrolled Asthma in China

    Dec 1, 2024, 00:00

  • HSD120 Evaluating Pre-Treatment Patient Pathways in Early Alzheimer's Disease Management: A Claims Data Analysis in Germany

    Dec 1, 2024, 00:00

  • HTA160 Structured Expert Elicitation in HTA Submissions: A Practical Guide Using the Example of Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma

    Dec 1, 2024, 00:00

  • HPR234 Access to Orphan Medicines in Portugal

    Dec 1, 2024, 00:00

  • HPR134 Impact of Loss of Exclusivity on the Expenditure of Medicines: An Analysis on Molecules for Which a Generic or Biosimilar Was Introduced in the Netherlands After 2012

    Dec 1, 2024, 00:00

  • HPR123 Assessment of Price Reduction Prediction Based on the Lasted Reimbursement Drug Renewal Rules in China

    Dec 1, 2024, 00:00

  • EE590 Economic Impact of Diabetes-Related Foot Amputations in Germany From the Payer's Perspective: An Extrapolation of German SHI Data

    Dec 1, 2024, 00:00

  • EPH133 AI Using Real-Life Data, an Additional Diagnostic Tool for Doctors to Identify Patient at Very High Risk of Renal Failure

    Dec 1, 2024, 00:00

  • EE760 Is There a Place for First-Generation mRNA Seasonal Influenza Vaccines? Unraveling the Clinical and Economic Consequences of Increased Reactogenicity in U.S. Older Adults

    Dec 1, 2024, 00:00

  • EE496 Relugolix/Estradiol/Norethisterone Compared to Tranexamic Acid for Symptomatic Uterine Fibroids in Premenopausal Women (20 to 40 YEAR Old): A Cost-Utility Analysis

    Dec 1, 2024, 00:00

  • HPR28 Access to Advanced Therapy Medicinal Products (ATMPs) in Low- and Middle-Income Countries LMICs: A Systematic Review

    Dec 1, 2024, 00:00

  • HTA188 Evaluating the Impact of Benefit Reassessment Outcomes for Orphan Drugs Surpassing the Revenue Limit in Germany

    Dec 1, 2024, 00:00

  • EE541 Cost-Effectiveness Analyses of Acute Ischemic Stroke Care Pathways: A Model for Different Scenarios and Countries

    Dec 1, 2024, 00:00

  • EE663 Budget Impact Analysis of Fracture Risk Assessment (FRAX) Based Treatment Strategy Selection in Patients With Glucocorticoid-Induced Osteoporosis (GIOP)

    Dec 1, 2024, 00:00

  • EE701 The Cost-Effectiveness of an AI-Based Population Wide Screening Programme of Primary Open-Angle Glaucoma in the Netherlands

    Dec 1, 2024, 00:00

  • EE699 The Benefit of Introducing Remimazolam for Procedural Sedation in Belgian Clinical Practice

    Dec 1, 2024, 00:00

  • EE338 Cost-Effectiveness of Cabotegravir Long-Acting for Pre-Exposure Prophylaxis Versus Current Use of Daily Oral Tenofovir Disoproxil Fumarate/Emtricitabine or No PrEP to Prevent HIV-1 in Individuals at High Risk in Spain

    Dec 1, 2024, 00:00

  • EE656 Challenges in Health-Economic Modeling of Phenylketonuria (PKU): A Targeted Review of HTA Evaluations

    Dec 1, 2024, 00:00

  • PT22 Evaluating Reimbursement Pathway of Digital Health Technologies (DHT) Across Five European Countries

    Dec 1, 2024, 00:00

  • EE419 Systematic Literature Review of Cost-Effectiveness Evaluations of Freestyle Libre Continuous Glucose Monitoring Systems

    Dec 1, 2024, 00:00

  • PT21 Promoting Access to Innovative Drugs: A Review of National Drug Price Negotiation in China

    Dec 1, 2024, 00:00

  • P6 Projected Increase of the Clinical, Economic, Societal, and Environmental Burdens of Chronic Kidney Disease in Switzerland: Insights from Impact-CKD

    Dec 1, 2024, 00:00

  • EE501 Cost-Effectiveness Analysis (CEA) of Pertuzumab and Trastuzumab (PH) + Chemotherapy (CT) Versus H + CT in HER2-Positive Early Breast Cancer (EBC): Updated Model Using Data From the 8.4-Year Follow-up of APHINITY

    Dec 1, 2024, 00:00

  • EE376 Rheumatoid Arthritis, Cost-Effectiveness Analysis of Biosimilar Tocilizumab in Spain

    Dec 1, 2024, 00:00

  • EE677 Consolidating Methods of Cost-Utility Analysis for Newborn Screening of Spinal Muscular Atrophy: A Systematic Review

    Dec 1, 2024, 00:00

  • HTA179 A Targeted Review of Treatment Beyond Progression in NICE HTA Oncology Submissions

    Dec 1, 2024, 00:00

  • EPH253 Retrospective Study of Treatment Patterns and Patient Characteristics of Patients With Prostate Cancer Treatment in Germany According to Castration Resistance and Metastatic Status

    Dec 1, 2024, 00:00

  • EE805 The Hazards of Applying Hazard Ratios to Accelerated Failure Time Models: A Simulation Study

    Dec 1, 2024, 00:00

  • EE812 Cost-Effectiveness of Donepezil, Galantamine, Rivastigmine and Memantine for Mild-to-Moderate and Moderate-to-Severe Alzheimer's Disease Patients in USA

    Dec 1, 2024, 00:00

  • HPR242 Lump-Sum Envelopes: High Predictability for Payers (Healthcare Product Pricing Committee – CEPS) and Minor Contribution for Companies

    Dec 1, 2024, 00:00

  • HPR40 Determinants of the Prices of Orphan Drugs in France

    Dec 1, 2024, 00:00

  • HTA194 Overview of NICE Cost-Comparison Technology Appraisals: Key Takeaways Regarding Comparator Selection and Methods Used to Demonstrate Comparable Efficacy

    Dec 1, 2024, 00:00

  • HTA161 Systematic Review With Indirect Comparison of Efficacy and Safety of Dupilumab Versus Omalizumab for Severe Asthma With Allergic Phenotype

    Dec 1, 2024, 00:00

  • EE651 Evaluating the Cost-Effectiveness of Dabrafenib and Trametinib for the Treatment of Pediatric Patients With Low-Grade Glioma Requiring Systemic Treatment in England and Wales

    Dec 1, 2024, 00:00

  • CO98 The Impact of Approved Anti-Obesity Medications on the Incidence of Osteoarthritis, Healthcare Resource Use and Costs Among Patients With Obesity: A Retrospective Cohort Study

    Dec 1, 2024, 00:00

  • EE788 Predicting Health Spending by Risk Level and Severity in a Colombian Health Promotion Entity

    Dec 1, 2024, 00:00

  • EE479 Real-World Evidence of Healthcare Utilization and Costs for Type 1 Diabetes and Severe Hypoglycemia by Age in Germany

    Dec 1, 2024, 00:00

  • CO46 Cognitive Assessments in Drug Development in Dementia and MCI: Clinical Trial Landscape Review and Recommendations for Future Neurodegenerative Studies

    Dec 1, 2024, 00:00

  • HTA98 Patient Consensus on PICO Scoping for the Health Technology Assessment (HTA) Regulation: A Case for Delphi Methodology

    Dec 1, 2024, 00:00

  • EPH277 Prevalence, Management, and Comorbid Condition Trends for Obesity Within US Self-Insured Employers

    Dec 1, 2024, 00:00

  • EPH177 A Multimodal Deep Neural Network for Early Prediction and Detection of Alzheimer's Disease Based on MRI Images and Clinical Information

    Dec 1, 2024, 00:00

  • HTA50 Characterizing Evidentiary Critiques in HTA Decision-Making for Treatments Indicated for Overweight and Obesity

    Dec 1, 2024, 00:00

  • HPR38 Top Trends Affecting the Vaccines Market and Their Implications on Access Policy and Public Health Decision-Making

    Dec 1, 2024, 00:00

  • EE382 Cost of Implementing Alectinib as an Adjuvant Treatment for ALK+ Non-Small Cell Lung Cancer in Denmark (C-ALINA)

    Dec 1, 2024, 00:00

  • HPR224 Utilization of Long-Term Care Before and After the 2015 Dutch National Reform: An Interrupted Time Series Analysis

    Dec 1, 2024, 00:00

  • EPH276 Predicting the Public Health Impact of Different Adult Pneumococcal Vaccines in Japan Using a Dynamic Transmission Model

    Dec 1, 2024, 00:00

  • EE671 Guidance for the Economic Evaluation of Prognostic and Predictive Companion Diagnostics: A Systematic Scoping Review

    Dec 1, 2024, 00:00

  • EE750 Cell-Based Therapies Reduce Costs and Knee Replacement Surgeries and Increase QALYs Among Knee Osteoarthritis Patients in the Netherlands: A Cost-Effectiveness Study

    Dec 1, 2024, 00:00

  • HTA210 Effectiveness of Generic Quality of Life (QoL) Questionnaires in Spinal Muscular Atrophy (SMA) and Duchenne Muscular Dystrophy (DMD)

    Dec 1, 2024, 00:00

  • HTA47 The Difference Between PICO Evaluation Across Australia, EU4, and UK

    Dec 1, 2024, 00:00

  • HSD22 Perceptions of Physicians on the Diagnosis of Rare Diseases in Europe: Results of a Cross-Sectional Survey

    Dec 1, 2024, 00:00

  • EE558 Economic Evaluations of Treatments for Acquired Hemophilia: A Systematic Literature Review

    Dec 1, 2024, 00:00

  • EPH175 Baseline Risk of Hospitalization and Death in a Nirmatrelvir/Ritonavir Treatment-Eligible Population With Mild-to-Moderate COVID-19 in the United States: A Systematic Literature Review

    Dec 1, 2024, 00:00

  • CO26 Encorafenib Plus Binimetinib Versus Dabrafenib Plus Trametinib in First-Line for Patients With Metastatic Non-Small Cell Lung Cancer Harboring BRAF V600E Mutation: Matching Adjusted Indirect Comparison of Pharos and BRF113928

    Dec 1, 2024, 00:00

  • EPH271 Dementia Awareness and Risk Factors Assessment: A Cross-Sectional Study of the Irish Population

    Dec 1, 2024, 00:00

  • HPR85 Socioeconomic Impact of Reverse Switching Over-the-Counter (OTC) Antifungal and Antiviral Medicines to Prescription Only Medicines (POM)

    Dec 1, 2024, 00:00

  • CO53 The Impact of Approved Anti-Obesity Medications on the Risk of Obstructive Sleep Apnea in Patients With Obesity: A Retrospective Cohort Study

    Dec 1, 2024, 00:00

  • HSD5 Real-World Survey on Treatment Pathways and Patterns for Patients With Primary Immune Complex Membranoproliferative Glomerulonephritis

    Dec 1, 2024, 00:00

  • HTA58 Methods Used to Adjust for Cross-Over in Clinical Trials: Insights From Scandinavian Health Technology Assessments

    Dec 1, 2024, 00:00

  • EE299 Economic Burden of Cardiovascular Diseases in Indonesia: Analysis of BPJS Kesehatan National Health Insurance Claims Data 2021-2022

    Dec 1, 2024, 00:00

  • HPR219 Studies on Health Economics and Outcomes From Türkiye Published in ISPOR by the Year 2024

    Dec 1, 2024, 00:00
  • «
  • 11
  • 12 (current)
  • 13
  • 14
  • 15
  • 16
  • 17
  • 18
  • 19
  • 20
  • »